Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» UCB Pharma
UCB Pharma
UCB chases after Argenx with FcRN drug for myasthenia gravis
Pharmaforum
Mon, 12/13/21 - 10:48 am
UCB Pharma
anti-FcRn
myasthenia gravis
rozanolixizumab
UCB Signs Up To $1.5 Bln Deal With Novartis To Co-develop Two Parkinson's Disease Drugs
NASDAQ
Thu, 12/2/21 - 10:39 am
Novartis
UCB Pharma
drug development
Parkinson's Disease
UCB to restrict 340B discounts to hospitals using community pharmacies
Beckers Hospital Review
Wed, 11/24/21 - 10:19 am
UCB Pharma
340B
hopsitals
drug discounts
AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis
Endpoints
Tue, 11/2/21 - 10:48 am
atopic dermatitis
eczema
nocturnal scratch
digital endpoint
AbbVie
Janssen
JNJ
Novartis
Pfizer
UCB Pharma
digital pharma
UCB licenses AI tech for spinal fracture detection to ImageBiopsy
Pharmaforum
Thu, 10/21/21 - 10:43 am
UCB Pharma
ImageBiopsy Lab
artificial intelligence
spinal fractures
diagnostics
Go or no go? UCB bids to make a mark in psoriasis
EP Vantage
Mon, 10/4/21 - 10:35 am
UCB Pharma
Bimzelx
psoriasis
From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year
Fierce Pharma
Mon, 09/13/21 - 11:38 pm
FDA
Pfizer
Argenx
UCB Pharma
Roche
efgartigimod
bimekizumab
faricimab
abrocitinib
FDA approves expanded indication for UCB’s Briviact to treat pediatric patients
Pharmaceutical Business Review
Tue, 08/31/21 - 10:57 am
UCB Pharma
FDA
partial onset seizures
pediatric
brivaracetam
The big approvals still on the cards for 2021
EP Vantage
Thu, 06/17/21 - 11:00 am
FDA
drug approvals
Argenx
Novartis
AstraZeneca
Astellas
UCB Pharma
Ascendis Pharma
ChemoCentryx
Axsome Therapeutics
Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021
PR Newswire
Tue, 03/9/21 - 10:45 am
Clarivate
Biogen
Eisai
aducanumab
UCB Pharma
bimekizumab
Relugolix
Pfizer
Takeda
Myovant
vericiguat
Bayer
Merck
UCB taps Microsoft to accelerate drug discovery, clinical trials
Fierce Biotech
Wed, 02/24/21 - 11:13 am
UCB Pharma
Microsoft
drug development
drug discovery
artificial intelligence
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
UCB backs epilepsy-focused digital heath startup Nile AI
Pharmaforum
Fri, 01/15/21 - 10:02 am
UCB Pharma
digital health
Nile AI
artificial intelligence
epilepsy
UCB accelerates ambitions in gene therapy with two deals
Pharma Letter
Thu, 11/12/20 - 10:51 am
gene therapy
UCB Pharma
M&A
Handl Therapeutics
Lacerta Therapeutics
Eli Lilly strikes deal to sell R&D campus to UCB
Fierce Biotech
Fri, 10/16/20 - 11:13 am
Eli Lilly
R&D
UK
UCB Pharma
Roche doubles down on Tau
EP Vantage
Wed, 07/29/20 - 12:20 pm
Roche
anti-tau antibodies
UCB Pharma
UCB01017
Alzheimer's disease
UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market
Endpoints
Fri, 07/24/20 - 11:17 am
UCB Pharma
psoriasis
bimekizumab
Cosentyx
UCB’s growth driver squares up against the competition
EP Vantage
Thu, 06/11/20 - 12:20 pm
UCB Pharma
bimekizumab
psoriasis
clinical trials
Novartis
Cosentyx
UCB buys epilepsy firm Engage Tx in $270m deal
PM Live
Mon, 06/8/20 - 10:30 am
UCB Pharma
epilepsy
M&A
Engage Therapeutics
drug-device combos
Staccato Alprazolam
UCB to build €300M biologics plant, add 150 workers
Fierce Pharma
Thu, 12/26/19 - 01:13 pm
UCB Pharma
biologics
drug manufacturing
Belgium
Pages
« first
‹ previous
1
2
3
4
next ›
last »